ArticleBlood2017
Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study.
Abstract read
In one paragraph
Article in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 145 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
145citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
145 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Newborn screening for severe combined immunodeficiency in the NHS newborn blood spot screening programme: a systematic review.Health technology assessment (Winchester, England) · 2026Pooled it
- Overview of next-generation sequencing to the molecular diagnosis of inborn errors of immunity in Brazil: a systematic review.Frontiers in immunology · 2026Pooled it
- Recommendations for uniform definitions used in newborn screening for severe combined immunodeficiency.The Journal of allergy and clinical immunology · 2022Pooled it
- Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment.Nature communications · 2024Trial
- Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC.Blood · 2022Trial
- T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy.British journal of haematology · 2019Trial
- Low Exposure Busulfan Conditioning to Achieve Sufficient Multilineage Chimerism in Patients with Severe Combined Immunodeficiency.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019Trial
- The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018).The Journal of allergy and clinical immunology · 2019Trial
- B-cell differentiation and IL-21 response inBlood · 2018Trial
- Clinical, immunological, and molecular characteristics of severe combined immune deficiency in China.Human genetics · 2026Article
- Second-tier genetics improves newborn screening accuracy for SCID and other T cell deficiencies.Journal of human immunity · 2026Article
- Nationwide TREC/KREC-based newborn screening and clinical outcomes in Japan.Journal of human immunity · 2026Article
- Newborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report.Journal of human immunity · 2026Article
- IMPACT (Immune Monitoring and Phenotype Assessment of Clinical Trajectory) for Patients With Inborn Errors of Immunity From the Primary Immune Deficiency Treatment Consortium (PIDTC).The journal of allergy and clinical immunology. In practice · 2026Article
- Evolution of Inborn Errors of Immunity in China: Discoveries and Treatment Paradigms.Clinical reviews in allergy & immunology · 2026Review
- Long-term outcomes and GVHD in allogeneic hematopoietic cell transplantation abroad: a 14-year UAE multi-center cohort.BJC reports · 2026Article
- Treosulfan-fludarabine conditioning in infants with severe combined immunodeficiencies: Extended study of the UK paediatric treosulfan study.British journal of haematology · 2026Article
- Allogeneic Hematopoietic Cell Transplantation for Congenital Athymia: A Nationwide Retrospective Study in Japan.Journal of clinical immunology · 2026Article
- Managing non-SCID T cell lymphopenia after TREC-based newborn screening.Journal of human immunity · 2026Article
- T-Cell Receptor Excision Circle/Kappa-Deleting Recombination Excision Circle-Based Newborn Screening Program for Severe Combined Immunodeficiency in Kumamoto, Japan.Cell biochemistry and biophysics · 2026Article
85 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Jennifer HeimallDivision of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, PA.
Brent R LoganDivision of Biostatistics, Medical College of Wisconsin, Milwaukee, WI.
Morton J CowanDivision of Pediatric Allergy, Immunology and Bone Marrow Transplant, University of California, San Francisco, San Francisco, CA.
Luigi D NotarangeloLaboratory of Host Defense, Division of Intramural Research, and.
Linda M GriffithDivision of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Jennifer M PuckDivision of Pediatric Allergy, Immunology and Bone Marrow Transplant, University of California, San Francisco, San Francisco, CA.
Donald B KohnDepartment of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Michael A PulsipherChildren's Hospital Los Angeles, University of Southern California, Los Angeles, CA.
Suhag ParikhDepartment of Pediatrics, Duke University, Durham, NC.
Caridad MartinezTexas Children's Hospital, Baylor College of Medicine, Houston, TX.
Neena KapoorChildren's Hospital Los Angeles, University of Southern California, Los Angeles, CA.
Richard O'ReillyMemorial Sloan Kettering Cancer Center, New York, NY.
Michael BoyerUniversity of Utah Health, Salt Lake City, UT.
Sung-Yun PaiBoston Children's Hospital, Boston, MA.
Frederick GoldmanDepartment of Pediatrics, University of Alabama at Birmingham, Birmingham, AL.
Lauri BurroughsFred Hutchinson Cancer Research Center, Seattle, WA.
Sharat ChandraCincinnati Children's Hospital, Cincinnati, OH.
Morris KletzelDivision of Pediatric Hematology, Oncology and Stem Cell Transplantation, Northwestern University, Evanston, IL.
Monica ThakarDivision of Pediatric Hematology/Oncology/Transplant, Medical College of Wisconsin, Milwaukee, WI.
James ConnellyDepartment of Pediatrics, Vanderbilt University, Nashville, TN.
Geoff CuvelierCancerCare Manitoba, Winnipeg, MB, Canada.
Blachy J Davila SaldanaDivision of Blood and Marrow Transplantation, Children's National Medical Center, Washington, DC.
Evan ShereckDivision of Pediatric Hematology/Oncology, Department of Pediatrics, Oregon Health and Science University, Portland, OR.
Alan KnutsenCardinal Glennon Children's Hospital, St. Louis, MO.
Kathleen E SullivanDivision of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, PA.
Kenneth DeSantesUniversity of Wisconsin-Madison, Madison, WI.
Alfred GillioHackensack University Medical Center, Hackensack, NJ.
Elie HaddadCHU Sainte-Justine, Department of Pediatrics, University of Montreal, Montreal, Canada.
Aleksandra PetrovicSeattle Children's Hospital, Seattle, WA.
Troy QuiggMethodist Children's Hospital of South Texas, San Antonio, TX.
Angela R SmithDivision of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN.
Elizabeth StengerChildren's Healthcare of Atlanta, Atlanta, GA; and.
Ziyan YinDivision of Biostatistics, Medical College of Wisconsin, Milwaukee, WI.
William T ShearerTexas Children's Hospital, Baylor College of Medicine, Houston, TX.
Thomas FleisherClinical Center, National Institutes of Health, Bethesda, MD.
Rebecca H BuckleyDepartment of Pediatrics, Duke University, Durham, NC.
Christopher C DvorakDivision of Pediatric Allergy, Immunology and Bone Marrow Transplant, University of California, San Francisco, San Francisco, CA.ORCID 0000-0002-6146-3952
Funding
Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2MPB vs. BMU01HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2001 to 2010
$63.3MRare Diseases Data Management and Coordinating CenterU01TR001263 · NCATS · UNIVERSITY OF SOUTH FLORIDA · PI KRISCHER, JEFFREY P · 2014 to 2018
$28.1MTraining of Clinical Investigators in Primary Immune DeficienciesU54AI082973 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PAI, SUNG-YUN · 2009 to 2023
$23.3MData Management and Coordinating Center (DMCC)U54NS064808 · NINDS · UNIVERSITY OF SOUTH FLORIDA · PI KRISCHER, JEFFREY P · 2009 to 2013
$16.5MCharacterization of the cellular and molecular bases of inborn errors of immunityZIAAI001222 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI NOTARANGELO, LUIGI · 2017 to 2025
$15.2MBlood and Marrow Transplant Clinical Trials NetworkU10HL069254 · NHLBI · UNIVERSITY OF UTAH · PI PULSIPHER, MICHAEL A · 2011 to 2016
$839kPrimary Immune Deficiency Treatment Consortium Annual Scientific MeetingR13AI094943 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PUCK, JENNIFER M. · 2011 to 2025
$239kNCATS NIH HHS U01 TR001263NCI NIH HHS U24 CA076518NHLBI NIH HHS U01 HL069294NHLBI NIH HHS U10 HL069254NIAID NIH HHS R13 AI094943NIAID NIH HHS U54 AI082973NINDS NIH HHS U54 NS064808
Abstract
The Primary Immune Deficiency Treatment Consortium (PIDTC) is enrolling children with severe combined immunodeficiency (SCID) to a prospective natural history study. We analyzed patients treated with allogeneic hematopoietic cell transplantation (HCT) from 2010 to 2014, including 68 patients with typical SCID and 32 with leaky SCID, Omenn syndrome, or reticular dysgenesis. Most (59%) patients were diagnosed by newborn screening or family history. The 2-year overall survival was 90%, but was 95% for those who were infection-free at HCT vs 81% for those with active infection (
Indexed as
Immune ReconstitutionChild, PreschoolFemaleGenotypeGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansInfantInfant, NewbornInfectionsMaleNeonatal ScreeningProspective StudiesRisk FactorsSevere Combined ImmunodeficiencySurvival Analysis
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.